固元醒脑汤联合奥拉西坦治疗轻度认知功能障碍效果分析
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

安徽省自然科学基金项目(编号:1308085QH149)


Research of Guyuan Xingnao Decoction Combined with Oxiracetam in the Treatment of Mild Cognitive Impairment
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察固元醒脑汤联合奥拉西坦对MCI患者临床疗效。方法:将60例MCI患者随机分成2组,治疗组采用固元醒脑汤联合奥拉西坦,对照组单用奥拉西坦,采用MMSE、MoCA、ADL量表评定,观察血清Aβ及IL-6变化,3周后考察其疗效。结果:治疗后治疗组MMSE、MoCA量表评分及Aβ、IL-6优于对照组,差异有统计学意义(P<0.05)治疗后2组MMSE、MoCA、ADL量表评分及Aβ、IL-6较治疗前有降低,差异有统计学意义(P<0.05),并且治疗组降分程度高于对照组,差异有统计学意义(P<0.05)。结论:固元醒脑汤联合奥拉西坦能明显降低MCI患者Aβ与IL-6水平,并可显著提高认知功能。

    Abstract:

    To observe the curative effect of Guyuan Xingnao Decoction combined with oxiracetam in patients with MCI. Methods: Sixty patients with MCI were randomly divided into two groups. The observation group was given Guyuan Xingnao Decoction and oxiracetam, and the control group was solely given oxiracetam. MMSE, MoCA, ADL were employed to assess the levels of Aβ and IL-6. Treatment duration lasted for three weeks. Results: After treatment, the MMSE, MoCA scale score and levels of Aβ and IL-6 were all better than those of the control group, and the results is of statistical difference (P<0.05). Compared with before, MMSE, MoCA, ADL scale score and Aβ, IL-6 of both groups were lower (P<0.05). Besides, the treatment group reduction degree of scores were larger than those of the control group (P<0.05). Conclusion: Guyuan Xingnao Decoction combined with oxiracetam can significantly decrease the Aβ and IL-6 levels in patients with MIC and improve their cognitive function.

    参考文献
    相似文献
    引证文献
引用本文

杨成,朱才丰,刘丽丽.固元醒脑汤联合奥拉西坦治疗轻度认知功能障碍效果分析[J].世界中医药,2015,10(06).

复制
相关视频

分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2015-03-29
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2015-06-24
  • 出版日期:
文章二维码